NCT01820715View on ClinicalTrials.gov

A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

April 30, 2013

Conditions
Diabetic Neuropathy
Interventions
DRUG

600㎍ of DA-3030 Injection

DRUG

Placebo

Trial Locations (1)

133-791

Hanyang University Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Dong-A Pharmaceutical Co., Ltd.

INDUSTRY

NCT01820715 - A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain | Biotech Hunter | Biotech Hunter